Drug-induced lung disease is one of those “don’t-miss” USMLE topics because it hides in plain sight: a patient on a common medication develops progressive dyspnea + dry cough + diffuse interstitial changes—and the fastest way to score points is to name the drug before you chase zebras. Here are 3 quick, shareable tips to lock in the highest-yield associations.
Tip 1: Always ask “A-A-A?” for interstitial lung disease
Amiodarone, Asbestos, Autoimmune
If you see restrictive physiology + interstitial findings, quickly screen for these big three—amiodarone is the drug-induced one you’re most likely to be tested on.
One-liner: Amiodarone can cause interstitial pneumonitis/fibrosis due to tissue accumulation (iodine-rich, highly lipophilic) → dry cough, dyspnea, diffuse interstitial opacities, often with a ↓DLCO.
High-yield clues
- PFTs: restrictive pattern (↓TLC) + ↓DLCO
- Imaging: diffuse interstitial infiltrates; can look like pulmonary fibrosis
- Timing: can be subacute or chronic (often months, but can vary)
- Management (testable): stop amiodarone; consider systemic glucocorticoids if significant pneumonitis
Tip 2: Know the “BAD Fibrosis Trio” (the classic Step association)
Bleomycin, Amiodarone, (high-dose) oxygen
This is a board-style cluster: the drug that causes pulmonary fibrosis (bleomycin), another that causes interstitial lung disease (amiodarone), and the factor that worsens bleomycin lung toxicity (high inspired O₂).
Visual mnemonic: “B.A.D. lungs + O₂ = worse”
- Bleomycin → Alveolar damage/fibrosis
- Amiodarone → Diffuse interstitial pneumonitis
- O₂ (especially high FiO₂) → can exacerbate bleomycin toxicity
One-liner: Bleomycin causes interstitial pneumonitis → fibrosis, and high inspired oxygen can make it worse (think perioperative oxygen exposure in a cancer patient).
High-yield clues
- Commonly tested in patients treated for testicular cancer or Hodgkin lymphoma (ABVD regimen)
- Bleomycin hydrolase is low in the lungs and skin → toxicity in those organs
- Toxicities: pulmonary fibrosis + skin hyperpigmentation/changes
Tip 3: Don’t confuse drug-induced interstitial disease with drug-induced bronchospasm
Not every medication-related dyspnea is restrictive/ILD—USMLE loves to bait you with wheeze.
Quick sorter
| Presentation | Likely pattern | Classic meds | Key clue |
|---|---|---|---|
| Dry cough + progressive dyspnea + crackles | Restrictive / ILD | Amiodarone, bleomycin, methotrexate, nitrofurantoin | ↓DLCO, interstitial changes |
| Wheeze + acute bronchospasm | Obstructive | Nonselective β-blockers, aspirin/NSAIDs (AERD) | Wheezing, reversible obstruction |
One-liner: If you hear wheezing, think bronchospasm/obstructive; if you hear dry crackles and see ↓DLCO, think interstitial drug toxicity.
Extra high-yield add-ons (common exam distractors)
- Methotrexate: can cause hypersensitivity pneumonitis/interstitial pneumonitis (dyspnea, cough, fever; diffuse infiltrates)
- Nitrofurantoin: can cause acute pneumonitis or chronic interstitial lung disease (especially with prolonged use)
The “30-second USMLE approach” to suspected drug-induced ILD
- Symptoms: progressive dyspnea + dry cough (± fever if hypersensitivity-type)
- Exam: inspiratory fine crackles
- PFT: restrictive + ↓DLCO
- Imaging: diffuse interstitial opacities/ground-glass/reticular changes
- Next step: stop the offending drug (and consider steroids if clinically significant)
Rapid recap (shareable)
- Amiodarone → interstitial pneumonitis/fibrosis (↓DLCO)
- Bleomycin → pulmonary fibrosis; high O₂ worsens toxicity
- Wheeze ≠ ILD: wheeze suggests bronchospasm (e.g., nonselective β-blockers), while ILD tends to be dry cough + crackles